糖尿病患者心血管疾病防治的新兴靶点。
Emerging Targets for Cardiovascular Disease Prevention in Diabetes.
机构信息
Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St Louis, MO 63110, USA; Department of Genetics, Washington University School of Medicine, St Louis, MO 63110, USA; McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO 63110, USA.
Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington Medicine Diabetes Institute, University of Washington School of Medicine, Seattle, WA 98109, USA.
出版信息
Trends Mol Med. 2020 Aug;26(8):744-757. doi: 10.1016/j.molmed.2020.03.011. Epub 2020 May 15.
Abstract
Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke. Recent clinical trials point toward new treatment and prevention strategies for cardiovascular complications of T2DM. New antidiabetic agents show unexpected cardioprotective benefits. Moreover, genetic and reverse translational strategies have revealed potential novel targets for CVD prevention in diabetes, including inhibition of apolipoprotein C3 (APOC3). Modeling and pharmacology-based approaches to improve insulin action provide additional potential strategies to combat CVD. The development of new strategies for improved diabetes and lipid control fuels hope for future prevention of CVD associated with diabetes.
摘要
1 型和 2 型糖尿病（T1DM 和 T2DM）会增加动脉粥样硬化性心血管疾病（CVD）的风险，导致急性心血管事件，如心脏病发作和中风。最近的临床试验指出了针对 T2DM 心血管并发症的新治疗和预防策略。新型抗糖尿病药物显示出意想不到的心脏保护益处。此外，遗传和反向转化策略揭示了糖尿病心血管疾病预防的潜在新靶点，包括抑制载脂蛋白 C3（APOC3）。改善胰岛素作用的建模和药理学方法为对抗 CVD 提供了额外的潜在策略。新策略的发展旨在改善糖尿病和血脂控制，为未来预防与糖尿病相关的 CVD 带来希望。
相似文献
1
Emerging Targets for Cardiovascular Disease Prevention in Diabetes.糖尿病患者心血管疾病防治的新兴靶点。
Trends Mol Med. 2020 Aug;26(8):744-757. doi: 10.1016/j.molmed.2020.03.011. Epub 2020 May 15.
2
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.恩格列净心血管结局研究（EMPA-REG）及其他降糖药物心血管结局试验：对2型糖尿病未来治疗策略的启示
Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.
3
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.2型糖尿病患者中与二肽基肽酶-4抑制剂及其他抗糖尿病药物相关的心血管疾病风险：一项全国性纵向研究
Cardiovasc Diabetol. 2016 Mar 1;15:41. doi: 10.1186/s12933-016-0350-4.
4
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.基于超过 500000 例 2 型糖尿病患者的数据，预测无心血管事件的个体寿命延长年数，基于血脂、血压、血糖和阿司匹林治疗。
Eur Heart J. 2019 Sep 7;40(34):2899-2906. doi: 10.1093/eurheartj/ehy839.
5
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.2型糖尿病中心血管疾病的流行病学现状及心血管风险管理趋势
Metabolism. 2021 Oct;123:154838. doi: 10.1016/j.metabol.2021.154838. Epub 2021 Jul 30.
6
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.用于治疗2型糖尿病的非胰岛素药物的心血管益处及安全性。
Postgrad Med. 2017 Nov;129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27.
7
Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.2 型糖尿病患者的高血糖和心血管危险因素的早期强化治疗。
Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025.
8
What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?我们从美国食品药品监督管理局（FDA）要求开展的新型抗糖尿病药物心血管结局研究中学到了什么？
Curr Diab Rep. 2016 Oct;16(10):94. doi: 10.1007/s11892-016-0788-5.
9
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.2型糖尿病治疗中的心血管保护：各类药物临床试验结果综述
Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008.
10
Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.心血管安全性和非胰岛素类抗高血糖药物在 2 型糖尿病治疗中的获益-第 1 部分。
Cardiol Rev. 2020 Jul/Aug;28(4):177-189. doi: 10.1097/CRD.0000000000000308.
引用本文的文献
1
Magnesium-assisted hydrogen improves isoproterenol-induced heart failure.镁辅助氢改善异丙肾上腺素诱导的心力衰竭。
Med Gas Res. 2025 Dec 1;15(4):459-470. doi: 10.4103/mgr.MEDGASRES-D-24-00135. Epub 2025 Apr 29.
2
Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.2 型糖尿病患者中风的影响因素：系统评价和荟萃分析。
PLoS One. 2024 Jun 24;19(6):e0305954. doi: 10.1371/journal.pone.0305954. eCollection 2024.
3
Explore the value of carotid ultrasound radiomics nomogram in predicting ischemic stroke risk in patients with type 2 diabetes mellitus.探讨颈动脉超声放射组学列线图在预测 2 型糖尿病患者缺血性脑卒中风险中的价值。
Front Endocrinol (Lausanne). 2024 Apr 19;15:1357580. doi: 10.3389/fendo.2024.1357580. eCollection 2024.
4
Causal associations between type 1 diabetes mellitus and cardiovascular diseases: a Mendelian randomization study.1 型糖尿病与心血管疾病之间的因果关联：一项孟德尔随机化研究。
Cardiovasc Diabetol. 2023 Sep 2;22(1):236. doi: 10.1186/s12933-023-01974-6.
5
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis.糖尿病加速动脉粥样硬化中的单核细胞和巨噬细胞泡沫细胞。
Front Cardiovasc Med. 2023 Jun 12;10:1213177. doi: 10.3389/fcvm.2023.1213177. eCollection 2023.
6
Predictive values of metabolic score for insulin resistance on risk of major adverse cardiovascular events and comparison with other insulin resistance indices among Chinese with and without diabetes mellitus: Results from the 4C cohort study.代谢评分预测胰岛素抵抗与中国糖尿病和非糖尿病患者主要不良心血管事件风险的关系：4C 队列研究结果。
J Diabetes Investig. 2023 Aug;14(8):961-972. doi: 10.1111/jdi.14024. Epub 2023 May 2.
7
New Progress in Early Diagnosis of Atherosclerosis.动脉粥样硬化早期诊断的新进展。
Int J Mol Sci. 2022 Aug 11;23(16):8939. doi: 10.3390/ijms23168939.
8
ER-Stress and Senescence Coordinately Promote Endothelial Barrier Dysfunction in Diabetes-Induced Atherosclerosis.内质网应激与衰老协同促进糖尿病性动脉粥样硬化中的血管内皮屏障功能障碍。
Nutrients. 2022 Jul 6;14(14):2786. doi: 10.3390/nu14142786.
9
Hypercoagulability Impairs Plaque Stability in Diabetes-Induced Atherosclerosis.高凝状态损害糖尿病诱导的动脉粥样硬化斑块稳定性。
Nutrients. 2022 May 10;14(10):1991. doi: 10.3390/nu14101991.
10
Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines.ω-3 脂肪酸降低甘油三酯：一种由 N-酰基牛磺酸介导的机制。
J Clin Invest. 2021 Mar 15;131(6). doi: 10.1172/JCI147558.
本文引用的文献
1
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.富含甘油三酯的脂蛋白残粒、糖尿病与心血管疾病。
Diabetes. 2020 Apr;69(4):508-516. doi: 10.2337/dbi19-0007.
2
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.依泽替米贝在 REDUCE-IT 试验中显著降低首发和全心血管事件：为何这些结果开创了血脂异常治疗的新时代。
Eur Heart J. 2020 Jun 21;41(24):2304-2312. doi: 10.1093/eurheartj/ehz778.
3
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.载脂蛋白 C3 通过替代炎性小体激活诱导炎症和器官损伤。
Nat Immunol. 2020 Jan;21(1):30-41. doi: 10.1038/s41590-019-0548-1. Epub 2019 Dec 9.
4
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.钠-葡萄糖协同转运蛋白 2 抑制剂相关心血管获益的潜在机制。
Am J Cardiol. 2019 Dec 15;124 Suppl 1:S36-S44. doi: 10.1016/j.amjcard.2019.10.028.
5
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes.肝靶向餐时胰岛素在 1 型糖尿病中具有不同的降血糖作用：一项 6 个月的 2b 期研究。
Diabetes Care. 2019 Nov;42(11):2154-2157. doi: 10.2337/dc19-0152. Epub 2019 Sep 24.
6
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
7
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.伏拉瑞斯森与家族性乳糜微粒血症综合征中的甘油三酯水平
N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944.
8
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.N-乙酰半乳糖胺修饰的抗载脂蛋白 C3mRNA 反义药物，用于降低甘油三酯和致动脉粥样硬化脂蛋白水平。
Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209.
9
Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.载脂蛋白 C3 升高可增加 1 型糖尿病患者的心血管风险。
J Clin Invest. 2019 Jul 11;129(10):4165-4179. doi: 10.1172/JCI127308.
10
Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.血清载脂蛋白和载脂蛋白定义的脂蛋白亚类：T1D 心血管事件的生成假说前瞻性研究。
J Lipid Res. 2019 Aug;60(8):1432-1439. doi: 10.1194/jlr.P090647. Epub 2019 Jun 15.
Zotero 插件